Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa Dose-Escalation Study Evaluating the Safety and Tolerability of CXL-1020 and Specific Effects on Electrocardiographic and Non-Invasive Hemodynamic Parameters in Patients With Chronic Heart Failure.

Trial Profile

A Phase I/IIa Dose-Escalation Study Evaluating the Safety and Tolerability of CXL-1020 and Specific Effects on Electrocardiographic and Non-Invasive Hemodynamic Parameters in Patients With Chronic Heart Failure.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CXL 1020 (Primary)
  • Indications Chronic heart failure; Heart failure
  • Focus Adverse reactions; Biomarker
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 06 Apr 2011 Results were presented at the Annual Meeting of the American College of Cardiology (ACC-2011).
  • 05 Apr 2011 Results presented at the 60th Annual Scientific Session of the American College of Cardiology.
  • 03 Aug 2010 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top